Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 3/20 | 0.38 |
| ▸ | CES1 | P23141 | 3/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6841032 | 1.00 | TSHR (0.47) | TSHRTHRBLMNAALDH1A1HSD17B10 | |
| SCHEMBL6841439 | 1.00 | TSHR (0.47) | TSHRTHRBLMNAALDH1A1HSD17B10 | |
| SCHEMBL968833 | 1.00 | TSHR (0.47) | TSHRTHRBLMNAALDH1A1HSD17B10 | |
| SCHEMBL6841495 | 1.00 | TSHR (0.47) | TSHRTHRBLMNAALDH1A1HSD17B10 | |
| SCHEMBL6841491 | 1.00 | TSHR (0.47) | TSHRTHRBLMNAALDH1A1HSD17B10 | |
| SCHEMBL968566 | 1.00 | TSHR (0.47) | TSHRTHRBLMNAALDH1A1HSD17B10 | |
| SCHEMBL1143377 | 0.97 | — | — | |
| SCHEMBL6841033 | 0.88 | — | — | |
| SCHEMBL13254747 | 0.87 | HDAC3 (0.41) | — | |
| SCHEMBL4521495 | 0.86 | ALDH1A1 (0.56) | TSHRALDH1A1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273726-B2 | Compositions for treating and/or preventing diseases characterized by the presence of metal ions | BRANDEIS UNIVERSITY (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273726-B2 | Compositions for treating and/or preventing diseases characterized by the presence of metal ions | BRANDEIS UNIVERSITY (US) | 2012-09-25 | — | — | US | disclosed |
| US-20100184724-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING DISEASES CHARACTERIZED BY THE PRESENCE OF METAL IONS | GRENPHARMA LLC (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184724-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING DISEASES CHARACTERIZED BY THE PRESENCE OF METAL IONS | GRENPHARMA LLC (US) | 2010-07-22 | — | — | US | disclosed |
| US-7595308-B2 | Treatment and/or prevention of Alzheimer's disease, other neurodegenerative diseases, and/or diseases characterized by the presence of certain metal ions, by using organosilicon compounds such as dichlorodiethylsilane | GRENPHARMA LLC (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595308-B2 | Treatment and/or prevention of Alzheimer's disease, other neurodegenerative diseases, and/or diseases characterized by the presence of certain metal ions, by using organosilicon compounds such as dichlorodiethylsilane | GRENPHARMA LLC (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090203644-A1 | Compositions for treating and/or preventing diseases characterized by the presence of metal ions | GRENPHARMA LLC (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203644-A1 | Compositions for treating and/or preventing diseases characterized by the presence of metal ions | GRENPHARMA LLC (US) | 2009-08-13 | — | — | US | disclosed |
| EP-1812013-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING DISEASES CHARACTERIZED BY THE PRESENCE OF THE METAL IONS | Grenpharma LLC (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006047477-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING DISEASES CHARACTERIZED BY THE PRESENCE OF THE METAL IONS | GRENPHARAMA LLC (US) | 2006-05-04 | — | — | WO | disclosed |
| US-20060040897-A1 | Compositions for treating and/or preventing diseases characterized by the presence of metal ions | GRENPHARMA, LLC | 2006-02-23 | — | — | US | disclosed |
| US-6764807-B2 | LITHOGRAPHY | KODAK POLYCHROME GRAPHICS LLC | 2004-07-20 | — | — | US | disclosed |
| US-20020086235-A1 | Lithography | EASTMAN KODAK COMPANY | 2002-07-04 | — | — | US | disclosed |
| US-6399271-B1 | HYDROXY CONTAINING COMPOUND WITH AFFINITY FOR INK, AND TITANIUM OR SILICON CONTAINING COMPOUND WITH DIFFERENT AFFINITY FOR INK | KODAK POLYCHROME GRAPHICS LLC | 2002-06-04 | — | — | US | disclosed |
| EP-0377175-A2 | Pattern forming composition and process for forming pattern using the same | HITACHI, LTD. (JP) | 1990-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184724-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING DISEASES CHARACTERIZED BY THE PRESENCE OF METAL IONS | FABP2, SLC3A2, SLC40A1 | TSHR 1785/4885THRB 1738/4885LMNA 1818/4885 |
| US-20060040897-A1 | Compositions for treating and/or preventing diseases characterized by the presence of metal ions | FABP2, SLC3A2, SLC40A1 | TSHR 1785/4885THRB 1738/4885LMNA 1818/4885 |
| US-20090203644-A1 | Compositions for treating and/or preventing diseases characterized by the presence of metal ions | APP, PSEN1, IAPP | TSHR 3968/4885THRB 3851/4885LMNA 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.